Nation-Wide Wastewater-Based Epidemiology Assessment of Metformin Usage in China: 2014–2020,ACS ES&T Water

当前位置： X-MOL 学术 › ACS ES&T Water › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Nation-Wide Wastewater-Based Epidemiology Assessment of Metformin Usage in China: 2014–2020
ACS ES&T Water ( IF 4.8 ) Pub Date : 2023-01-03 , DOI: 10.1021/acsestwater.2c00489
Qiuda Zheng _{1,

2} , Peng Du ₁ , Zhe Wang ₂ , Lingrong Zhang ₁ , Zhu Zhu ₁ , Jingjing Huang ₃ , Zhenglu Wang ₄ , Wayne Hall ₂ , Anh Kim Dang _{2,

5} , Degao Wang ₆ , Xiqing Li ₃ , Phong K. Thai ₂

Affiliation

Metformin, the unique first choice medicine for type 2 diabetes (T2D) in the US and Europe, was not widely adopted in China until recently. We measured metformin in wastewater samples, collected in major cities in China every 2 years from 2014 to 2020, to understand spatial and temporal trends of metformin use in T2D treatment in China. The estimated metformin use (mg/day/person) increased significantly from 1.6 ± 1.8 in 2014 to 4.2 ± 3.6 in 2016, then to 7.0 ± 8.8 in 2018, and 9.2 ± 9.0 in 2020. Metformin use increased nationally and in all seven geographical regions. Our findings reflect the broader uptake of metformin for treatment of T2D in China in accordance with expert recommendations. There was higher metformin use in the North than in the South of China, reflecting similar spatial trends in obesity rate in China. Wastewater analysis is likely to be a cost-effective way to monitor T2D treatment across China in the future.

更新日期：2023-01-03

点击分享查看原文

点击收藏

阅读更多本刊新发论文